The IVO-LUNG Study

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2029

Conditions

Non Small Cell Lung Cancer (Stage III)

Interventions

DRUG

Ivonescimab

Ivonescimab is given after definitive concurrent/sequential chemoradiotherapy

Trial Locations (1)

Li-Kun Chen, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER